| miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts AM Eiring, JG Harb, P Neviani, C Garton, JJ Oaks, R Spizzo, S Liu, ... Cell 140 (5), 652-665, 2010 | 699 | 2010 |
| FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia P Neviani, R Santhanam, JJ Oaks, AM Eiring, M Notari, BW Blaser, S Liu, ... The Journal of clinical investigation 117 (9), 2408-2421, 2007 | 429 | 2007 |
| Pushing the limits of targeted therapy in chronic myeloid leukaemia T O'hare, MS Zabriskie, AM Eiring, MW Deininger Nature Reviews Cancer 12 (8), 513-526, 2012 | 351 | 2012 |
| BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia MS Zabriskie, CA Eide, SK Tantravahi, NA Vellore, J Estrada, FE Nicolini, ... Cancer cell 26 (3), 428-442, 2014 | 344 | 2014 |
| Sp1/NFêB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia S Liu, LC Wu, J Pang, R Santhanam, S Schwind, YZ Wu, CJ Hickey, J Yu, ... Cancer cell 17 (4), 333-347, 2010 | 289 | 2010 |
| PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells P Neviani, JG Harb, JJ Oaks, R Santhanam, CJ Walker, JJ Ellis, ... The Journal of clinical investigation 123 (10), 4144-4157, 2013 | 259 | 2013 |
| BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships JS Khorashad, TW Kelley, P Szankasi, CC Mason, S Soverini, LT Adrian, ... Blood, The Journal of the American Society of Hematology 121 (3), 489-498, 2013 | 253 | 2013 |
| Zebrafish screen identifies novel compound with selective toxicity against leukemia S Ridges, WL Heaton, D Joshi, H Choi, A Eiring, L Batchelor, P Choudhry, ... Blood, The Journal of the American Society of Hematology 119 (24), 5621-5631, 2012 | 168 | 2012 |
| Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia AM Eiring, BDG Page, IL Kraft, CC Mason, NA Vellore, D Resetca, ... Leukemia 29 (3), 586-597, 2015 | 145 | 2015 |
| Age-related mutations and chronic myelomonocytic leukemia CC Mason, JS Khorashad, SK Tantravahi, TW Kelley, MS Zabriskie, ... Leukemia 30 (4), 906-913, 2016 | 142 | 2016 |
| High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2–dependent suppression of C/EBPá-driven myeloid differentiation JS Chang, R Santhanam, R Trotta, P Neviani, AM Eiring, E Briercheck, ... Blood, The Journal of the American Society of Hematology 110 (3), 994-1003, 2007 | 128 | 2007 |
| Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors E Traer, R MacKenzie, J Snead, A Agarwal, AM Eiring, T O'Hare, ... Leukemia 26 (5), 1140-1143, 2012 | 124 | 2012 |
| A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia M Wagle, AM Eiring, M Wongchenko, S Lu, Y Guan, Y Wang, M Lackner, ... Leukemia 30 (7), 1493-1501, 2016 | 72 | 2016 |
| Advances in the treatment of chronic myeloid leukemia AM Eiring, JS Khorashad, K Morley, MW Deininger BMC medicine 9, 1-6, 2011 | 72 | 2011 |
| Lenalidomide-mediated enhanced translation of C/EBPá-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia CJ Hickey, S Schwind, HS Radomska, AM Dorrance, R Santhanam, ... Blood, The Journal of the American Society of Hematology 121 (1), 159-169, 2013 | 67 | 2013 |
| miR-155 promotes FLT3-ITD–induced myeloproliferative disease through inhibition of the interferon response JA Wallace, DA Kagele, AM Eiring, CN Kim, R Hu, MC Runtsch, ... Blood, The Journal of the American Society of Hematology 129 (23), 3074-3086, 2017 | 64 | 2017 |
| Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis AM Eiring, P Neviani, R Santhanam, JJ Oaks, JS Chang, M Notari, ... Blood, The Journal of the American Society of Hematology 111 (2), 816-828, 2008 | 57 | 2008 |
| â-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia AM Eiring, JS Khorashad, DJ Anderson, F Yu, HM Redwine, CC Mason, ... Leukemia 29 (12), 2328-2337, 2015 | 53 | 2015 |
| shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance JS Khorashad, AM Eiring, CC Mason, KC Gantz, AD Bowler, HM Redwine, ... Blood, The Journal of the American Society of Hematology 125 (11), 1772-1781, 2015 | 49 | 2015 |
| Targeting LFA-1 and cd154 suppresses the in vivo activation and development of cytolytic (cd4-Independent) CD8+ T cells KE Lunsford, MA Koester, AM Eiring, PH Horne, D Gao, GL Bumgardner The Journal of Immunology 175 (12), 7855-7866, 2005 | 41 | 2005 |
